Document is current
Any future updates will be listed below
-
Authors
Costa-Verdera, Helena https://orcid.org/0000-0002-0750-2156
Collaud, Fanny https://orcid.org/0000-0002-2901-7290
Riling, Christopher R.
Sellier, Pauline
Nordin, Jayme M. L.
Preston, G. Michael
Cagin, Umut
Fabregue, Julien
Barral, Simon
Moya-Nilges, Maryse
Krijnse-Locker, Jacomina
van Wittenberghe, Laetitia
Daniele, Natalie
Gjata, Bernard
Cosette, Jeremie
Abad, Catalina
Simon-Sola, Marcelo
Charles, Severine
Li, Mathew
Crosariol, Marco
Antrilli, Tom
Quinn, William J. III
Gross, David A.
Boyer, Olivier https://orcid.org/0000-0002-7591-307X
Anguela, Xavier M.
Armour, Sean M. https://orcid.org/0000-0003-4297-4324
Colella, Pasqualina https://orcid.org/0000-0002-4268-2391
Ronzitti, Giuseppe https://orcid.org/0000-0002-9184-0210
Mingozzi, Federico https://orcid.org/0000-0003-0685-3752
- License Information
-
More Information
Article History
Received: 16 February 2021
Accepted: 5 October 2021
First Online: 4 November 2021
Competing interests
: F.M., P.C., and G.R. are inventors in patents applications concerning the treatment of Pompe disease by AAV licensed to Spark Therapeutics (WO2018046774, WO2018046775, and WO2018046775). S.M.A., J.M.L.N., and X.M.A. are inventors in a patent application describing the optimization of the secretable GAA transgene owned by Spark Therapeutics (WO2019222411). C.R.R., J.M.L.N, G.M.P., M.L., M.C., T.A., W.J.Q.III, X.M.A., S.M.A., and F.M. are either current or past employees and equity holder of Spark Therapeutics, Inc., a Roche company. H.C.V., P.S., U.C., J.F., S.B., M.N.-N., J.K.-L., L.v.W., N.D., B.G., J.C., C.A., M.S.-S., S.C., D.G., and O.B. declare no competing interests. This work was partially supported by Spark Therapeutics under a sponsored research agreement to Genethon.
